enzastaurin has been researched along with tandutinib in 3 studies
| Studies (enzastaurin) | Trials (enzastaurin) | Recent Studies (post-2010) (enzastaurin) | Studies (tandutinib) | Trials (tandutinib) | Recent Studies (post-2010) (tandutinib) |
|---|---|---|---|---|---|
| 188 | 52 | 99 | 69 | 5 | 41 |
| Protein | Taxonomy | enzastaurin (IC50) | tandutinib (IC50) |
|---|---|---|---|
| Integrin beta-3 | Homo sapiens (human) | 0.22 | |
| Macrophage colony-stimulating factor 1 receptor | Homo sapiens (human) | 3.43 | |
| Integrin alpha-IIb | Homo sapiens (human) | 0.22 | |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 0.149 | |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | 0.1867 | |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | 0.17 | |
| Cannabinoid receptor 1 | Rattus norvegicus (Norway rat) | 0.2 | |
| Fibroblast growth factor receptor 2 | Homo sapiens (human) | 0.17 | |
| Fibroblast growth factor receptor 4 | Homo sapiens (human) | 0.17 | |
| Fibroblast growth factor receptor 3 | Homo sapiens (human) | 0.17 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 2.07 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 0.9345 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.2 | |
| Cannabinoid receptor 2 | Rattus norvegicus (Norway rat) | 0.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
3 other study(ies) available for enzastaurin and tandutinib
| Article | Year |
|---|---|
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |